文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > Calcium supplementation and kidney stone risk in osteoporosis a systematic literature review
侵权投诉

Calcium supplementation and kidney stone risk in osteoporosis a systematic literature review

Calcium supplementation and kidney stone risk in osteoporosis a systematic literature review

Table III. Main characteristics of the included studies.

Intervention Outcomes Quality*/comments

Study Population

Oxford 2b-c

Oxford 1c

Domrongkitchaiporn (14), 2002 RCT, 3 m follow-up

Vit D 800 UI/d Calcium suppl 1.000 mg/d Vit D 800 UI/d + calcium 1.000 mg/d Placebo Serum calcium Nephrolithiasis

Grant (15), 2005 double-blind placebo control RCT, 2 yr follow-up

Urinary calcium ALP Hidroxiproline excretion Nephrolithiasis

n=61 (n=31 calcium + oestrogen therapy, mean age: 54 yr; n=30 calcium, mean age: 66 yr) IC: PM women with OP EC: prior use of drugs affecting bone metabolism

n=5.292 (n=1.306 vit D + calcium suppl; n=1.343 vit D; n=1.311 calcium suppl; n=1.332 palcebo), mean age 77 yr, 85% women IC: ≥70 yr with OP fracture within 10 yr EC: bed or chair bound, cognitive impairment, cancer, renalstone, daily intake ≥200 IU vitamin D or ≥500 mg calcium supplements; intake in the past 5 years of bisphosphonates, calcitonin, hormonereplacement therapy

Calcium suppl 625 mg/d + conjugated equine oestrogen 0.625 mg/d and 5 mg medrogestone acetate/d from day 1 to 12 of each month Calcium 625 mg/d Urinary excretion of calcium, oxalate, citrate, phosphate Calcium/citrate ratio AP(CaOx) index Nephrolithiasis

Oxford 2b-c 29 dropouts (6 group 1; 8 group 2; 3 group 3; 12 group 4)

Hasling (16), 1994 RCT, 3 yr follow-up

Calcitonin 200 IU/d intranasal 1 m on-1 m off + vit D 0.25 μgr/d + calcium suppl 500 mg/d Vit D 0.25 μgr/d + calcium suppl 500 mg/d Urinary calcium ALP Ca/creatinine ratio Pyrilinks-D/creatinine ratio iPTH

n=74: cyclic oestrogen/progestogen therapy (group 1, n=20), calcium suppl (group 2, n=17), intermittent cyclic etidronate therapy (group 3, n=19), ADFR treatment with T3 as activator and etidronate as depressor (group 4, n=18) CI: PM women (52–75 yr) with spinal crush fracture OP CE: treatments that alter bone or calcium metabolism, alcohol abuse, thyroid disorders, abnormalities of renal or hepatic function prior treatment for OP Oestrogen + progestogen: 2 mg estradiol/1 mg estriol 1/d x 12 d é 2 mg estradiol/1 mg estriol /1 mg norethisteronacetate 1/d days 13-22 é 1mg estradiol/0.5 mg estriol 1/d from day 23 to 28 + calcium suppl 120 mg/d Calcium suppl 2.000 mg/d Etidronate 400 mg x 2 w é 13 w etidronate free (10 cycles) + calcium suppl 120 mg/d ADFR (cycles): 50 μgr T3 2/d x 1 w + etidronate 400 mg 2v/d x 2 w é 13 w etidronate free + calcium suppl 120 mg/d

Oxford 2a-b 11 dropouts (7 calcitonin group; 4 in vit D +calcium group)

958

iPTH 400 UI/d sc + vit D 400 UI/d + calcium dietary and suppl 1.500 mg/d Placebo

Hydrochlorothiazide 44 mg ± 9 mg/d Calcium suppl 1.100mg ± 251 mg/d + vit D 1.277 UI ± 685 IU/d

TPTD 20 μg/d sc + calcium suppl 1.000 mg/d + vit D 400–1.200 UI/d TPTD 40 μg/d sc + calcium suppl 1.000 mg/d + vit D 400–1.200 UI/d Placebo

Calcium suppl 1.000 mg/d (effervescent) Calcium suppl 1.000 mg/d (carbonate) Calcium suppl 1.200 mg/d (carbonate)

Calcium suppl 1.200 mg/d Placebo

Alendronate 5 mg/d

Kaskani (17), 2005 Open RCT, 1 yr follow-up n=102 (n=57 calcitonin + vit D + calcium suppl, mean age 59 yr; n=45 vit D + calcium suppl, mean age 58 yr) IC: PM women (51–70 yr) without any kind of medication that could affect bone metabolism for at least 6 m before EC: secondary OP, kidney or hepatic insuf ciency, cancer, hematological diseases, thyroid diseases, treatment with thyroxin, chronic diseases that affect bone metabolism

Oxford 1c

Urinary calcium Nephrolithiasis

Oxford 2b

Urinary calcium Neprholithiasis Oxford 1c 7 dropouts (4 women y 1 man in TPTD 20 μg group; 1 woman in TPTD 40 μg group, 2 women in the placebo group)

Urinary calcium Urinary hidroxiproline

Neprholithiasis

Oxford 3b

Legroux-Gerot (19) , 2004 Prospective study, 18 m follow-up

Kurland (18), 2000 double-blind placebo control RCT, 18 m follow-up

Need (21),1991 RCT, 3 d follow-up

Miller (20), 2007 2 parallel double-blind placebo-controlled RCT 1 yr follow-up

n=27 (n=14 hydrochlorothiazide, mean age 53 yr; n=13 calcium suppl + vit D, mean age 48 yr) IC: hypercalciuretic osteoporotic male patients

n=23 (n=10 iPTH + vit D + calcium, mean age 54 yr; n=13 placebo, mean age 49 yr) IC: men (30–60 yr) and idiopatic OP (z-score <-2.0 or a T-score <-2.5 at the lumbar spine or femoral neck) EC: OP drugs in the previous 6 m Urinary calcium Serum calcium 1-25 dihidroxivitamine D Osteocalcin Urinary N-telopéptido

Study 1: n=1.637 PM women, mean age 69 yr Study 2: n=437 men, mean age 58 yr IC: OP patients or patients with low bone mass EC: nephrolithiasis or urolithiasis, impaired hepatic or renal function, diseases or drugs that alter bone metabolism in the previous 2–24 m

Recker (22), 1996 double-blind placebo control RCT, 1 yr follw-up

n=35 women mean age 68 yr IC: hospitalised PM women with OP

Yasui (23), 2009 prospective cohort, 3 m follow-up n=12, mean age: 63 yr IC: PM women with OP and had stones comprised of calcium phosphate, calcium oxalate or both EC: prior treatments for OP, primary hyperparathyroidism, renal tubular acidosis or other metabolic conditions associated with urinary tract infections or renal failure

n=197 (n=94 prevalent fractures, mean age 75 yr; n=103 non prevalent fractures, mean age 72 yr) IC: women >60 yr living independently and consuming <1 g/day of calcium

Oxford 2c

Urinary calcium Urinary oxalate Urinary phosphate AP(CaP) index AP(CaOx) index Nephrolithiasis

Oxford 2b

RCT: randomised controlled trial; IC: inclusion criteria; EC: exclusion criteria; OP: osteoporosis; PM: postmenopausal; suppl: supplement; vit: vitamin; yr: year; m: moth; w: week; d: day; mg:milligram; μgr: microgram; Ca: calcium; AP(CaOx): ion activity product of calcium oxalate salts in urine; sc: subcutaneous; T3: triiodothyronine; ADFR: activate, depress, free, repeat; GC: glucocorticoids; ALP: alkaline phosphatase; iPTH: intact parathormone; PTH: parathormone; TPTD: teriparatide; BMD: bone mineral density; RA: rheumatoid arthritis.

上一页第5页

你可能喜欢

热门文档

相关文档

  • 2013 lancet...

    Ian Reid and colleagues1 did a systematic review...calcium supplementation, baseline concentration of 25...risk in women with postmenopausal osteoporosis ...

  • ...status of research on osteoporosis

    Current status of research on osteoporosis in COPD: a systematic review L....interventions in osteoporosis, bisphosphonates, calcium supplementation, vitamin D...

  • ...D3) on the risk of fall and fracture a meta-anal...

    calcium as part of the 191 osteoporosis management...Can vitamin D supplementation reduce the risk of ...falls in older persons: a systematic review. ...

  • ...of Glucocorticoid-Induced Osteoporosis

    osteoporosis, as well as systematic reviews and meta-analyses of previously ...Other data support the effectiveness of calcium and vitamin D supplementation ...

  • Calcium Supplement Guidelines课件

    Calcium and Disease Prevention Osteoporosis ...levels actually reduces kidney stone formation risk... calcium supplementation may be necessary to obtain...

  • Osteoporosis_ the role of micronutrients

    Osteoporosis: the role of micronutrients1– 4 ...Calcium supplementation and increases in bone ...older adults: a systematic review and meta-...

  • journal.pon...

    Calcium supplementation was used in 26 trials (6...Discussion We conducted a systematic review and ...patients with osteoporosis and fracture risk [84]...

  • 831.full

    Guided by systematic reviews of evidence in ... osteoporosis, chronic kidney disease, liver ...A daily supplementation of 1,000 IU of vitamin ...

  • 201211Calcium Supplement Guidelines

    ? Osteoporosis Osteoporosis means “porous bone,”...levels actually reduces kidney stone formation risk... calcium supplementation may be necessary to obtain...

  • influence of vitamin D supplementation on serum 25-...

    Data Sources: We conducted a systematic search in...health and preventing osteoporosis and falls (1, ...Calcium plus vitamin D supplementation and the ...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email